Directory · SE
Biotechnology in Sweden
A register of firms and the professionals working at them in the Biotechnology sector based in Sweden. Browse the public index, then filter or export on Kipplo.
Companies
61 on file
Tataa Biocenter
At TATAA Biocenter, we offer PCR bioanalytical services to address the challenges in nucleic acid therapy drug development. Our mission as a CRO is to provide assay development, validation, and high-throughput analyses with high sensitivity for regulated and non-regulated bioanalysis, clinical biomarkers, and manufacturing quality assessments to accelerate your time-to-market. As your extended workbench of specialists and dedicated partner, we prioritize quality, innovation, and building strong client relationships. We are a GLP-accredited, GCLP-compliant, and ISO/IEC 17025-certified laboratory. Our purpose-built facility for nucleic acid analyses enhances sensitivity and minimizes contamination risks. With state-of-the-art instrumentation and an IT structure ensuring the highest data integrity and sample management, our collaborative and highly skilled scientists deliver advanced competence and precise execution.
51 to 200 staff
Cellectricon
At Cellectricon, we create new avenues for neuroscience drug discovery. Our mission is to create outstanding value for our Clients through highly customized in vitro neurobiology services delivering scientific excellence, innovation, and quality of the highest of standards. With a broad platform for in vitro neurobiology research, we help you to: • Accelerate your early R&D process and reduce your time-to-decision making • Obtain novel insights into disease biology and identify targets and lead compounds with potential to produce first-in-class medicines • Benefit from truly collaborative services where scientific exchange and open communication are prioritized to ensure project success Our unique discovery platform combines drug discovery expertise and disease area knowledge with cutting-edge technologies. With the platform, we create complex disease models and assays for functional and morphological screening. We have established service modules in the areas of Neuroinflammation, Peripheral Neuropathies, Neurodegeneration and Neuroplasticity. Through our services, we can accelerate your target and lead discovery programs.
11 to 50 staff
Affibody Ab
Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. The company operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that targets psoriasis, and B-cell driven autoimmune diseases respectively. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. Affibody has ongoing commercial relationships with several companies such as AbClon, Alexion, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum. Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Affibody AB is a holding of Patricia Industries.
51 to 200 staff
Cellcolabs
Cellcolabs mission is to prevent and treat diseases by making high quality stem cells available and affordable. We do that by industrial scale production and collaborations.
51 to 200 staff
Rarity Bioscience
Rarity Bioscience provides ultra-sensitive multiplex assays for mutation detection in blood and other liquid biopsies for research, pharma and labs. The superRCA technology is based on padlock probes and rolling circle amplification, enabling extreme sensitivity and specificity, and utilize well established high throughput flow cytometry for the read-out. The company was founded in 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology, and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala University.
11 to 50 staff
Bergmanlabora Ab
BergmanLabora AB är en av Sveriges ledande leverantörer till den svenska laboratoriemarknaden. Vårt huvudkontor ligger i Danderyd med filial i Göteborg. BergmanLaboras affärsidé är att tillhandahålla instrument från världens främsta tillverkare av labinstrument och produkter för mikroskopi. Vi utför teknisk service så instrumenten ger tillförlitliga resultat under hela livslängden samt förmedlar kunskap om applikationer och handhavande. BergmanLabora AB ingår i AddLife AB, noterad på Nasdaq OMX Stockholm (notering 16 mars 2016). AddLife förenar det större bolagets styrka med entreprenörens engagemang och affärsmannaskap. Våra systerbolag inom lab är BioNordika i Sverige, Holm & Halby i Danmark, BioNordika Bergman i Norge och BioNordika OY i Finland. Företaget grundades 1906 och har byggt framgångarna på att hjälpa kunder att finna lösningar på enklaste och mest effektiva sätt. Våra säljare, produktspecialister, innesäljare samt servicetekniker har mycket goda kund- och produktkunskaper. Genom en hög servicegrad, lättillgänglighet och en väl fungerande logistik ger vi våra kunder högsta prioritet. Söker du totallösningar hjälper vi till med installation, igångkörning, validering, utbildning och service. Vi står också för snabba leveranser av apparater/instrument, tillbehör och förbrukningsartiklar till instrumenten. Huvudleverantörer hos BergmanLabora- Nikon - Büchi - Cole Parmer - Integra - Radiometer - Sotax - Andor Technology - CoolLed - Lumenera - Narishige
11 to 50 staff
Bioteria
Bioteria är ett miljöteknikföretag som utvecklar och marknadsför produkter och tjänster inom avloppsvattenbehandling, avfallshantering, storköksventilation- och hygien. Bioteria is a cleantech company that develops and market products and services for waste water treatment, wast treatment and kitchen hoods.
51 to 200 staff
Cereno Scientific
Cereno Scientific is pioneering treatments to enhance and extend life. The innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Cereno Scientific is advancing a pipeline that includes an HDACi portfolio with two drug candidates in clinical phase – CS1 in pulmonary arterial hypertension (PAH) and CS014 in idiopathic pulmonary fibrosis (IPF). The HDACi portfolio has an innovative disease-modifying approach to addressing the root mechanism of rare and fatal diseases, untapping the potential of epigenetic modulation in rare cardiovascular and pulmonary diseases. In preclinical stage, the pipeline comprises the drug candidate CS585, a novel prostacyclin (IP) receptor agonist, that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. Cereno Scientific has the potential to deliver high treatment value to people that are suffering from rare cardiovascular and pulmonary diseases who today have unmet medical needs. The Company is headquartered in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B).
11 to 50 staff
Active Biotech Ab
Active Biotech AB (publ)(NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit for more information.
1 to 10 staff
Bionordika Sweden Ab
BioNordika Sweden AB offers a wide and unique selection of products and services within the areas of Cell- and Molecular Biology. Our extensive knowledge about advanced life science applications gives us the opportunity to guide you to the right products for your research- PCR/qPCR - NGS library prep - Restriction enzymes - Cloning - Electrophoresis - Antibodies - Primary cells and cell culture media - FISH probes - Endotoxin detection - Assay kits for biomedical research - Molecular diagnostics - Custom services We are a part of AddLife, a company listed on Nasdaq Stockholm. BioNordika are also represented in Denmark, Norway, Finland, and Baltics.
11 to 50 staff
Simsen Diagnostics
We develop technologies for ultrasensitive analysis of complex DNA sources. Compared to other technologies for ultrasensitive sequencing, our solutions are both simple to use and specifically adapted for analysis of difficult to analyze DNA such as circulating tumor DNA, a biomarker specific for cancer.
1 to 10 staff
Melt&marble
Melt & Marble is dedicated to enabling the transition towards a more sustainable future by revolutionizing the production of fats. Melt & Marble’s technology allows the production of any fat from simple feedstocks, without relying on unsustainable animal and plant sources. This technology allows Melt & Marble to deliver innovative, tailor-made fat solutions with improved sustainability, functionality, and health profile for the food industry and beyond.
11 to 50 staff
Nyctea Technologies
We are providing electronically activated purification of biomolecules for biopharmaceutical and protein production. By utilizing our patent-pending invention, we build functionalized polymer surfaces that can with high specificity and high capacity capture and release biomolecules at the press of a button. Making today's complex biopharmaceutical and protein manufacturing simpler, more effective, and digital.
1 to 10 staff
3h Biomedical Ab
3H Biomedical is an innovative life-science company that discovers, develops and distributes human cell-based products and technologies for life science research, drug development and tissue engineering. We take pride in our contribution to improving human health and environment. Our mission is to help scientists be more productive, more competitive and more innovative. Serving the global research community, biotech sector and pharmaceutical industry. We supply more than 260 different types of primary human cells, media and cell-based products. R&D projects: EUROSTARS: PREVAIL Preclinical development of novel ERRalpha inhibitors for treatment of Triple Negative Breast Cancer. The PREVAIL project will deliver a first-in-class targeted therapeutic for treatment of triple negative breast cancer (TNBC). SEAL OF EXCELLENCE Next generation of targeted dendritc cell vaccine for cancer treatment, a therapeutic cancer vaccine technology platform. We are actively seeking partners in the pharmaceutical industry and clinical centres in order to co-develop our patented vaccine technology.
1 to 10 staff
Alzinova Ab
Alzinova AB is a Swedish clinical-stage biopharma company developing treatments for Alzheimer’s disease by specifically targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that has unique ability and precision to target the toxic amyloid-beta oligomers involved in the onset and progression of the disease. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further.
1 to 10 staff
Annexin Pharmaceuticals Ab Publ
Annexin Pharmaceuticals AB (publ) is a world-leading biotechnology company in the Annexin A5 field, for the treatment of various cardiovascular diseases. The Company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for the acute treatment of patients with cardiovascular diseases with vascular damages and inflammation. The Company also has a comprehensive patent portfolio for the treatment of diseases caused by vascular damage and inflammation. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of Annexin A5. The production process is patented. ANXV has the ability to protect and repair the blood vessels as well as counteract the inflammation. ANXV is therefore expected to reduce suffering and hopefully mortality for several patient groups with both rare vascular diseases and major ones, such as heart attack. ANXV has the potential to become a First-In-Class drug (a product with new and unique mechanisms of action which is the first of its kind on the market) for several patient groups where there is considerable unmet demand for medical treatment.
1 to 10 staff
Diagonal Bio
Diagonal Bio is a dynamic and innovative company that develops a groundbreaking platform technology for ultra-fast, easy-to-use, and accurate detection of genetic markers. The company was founded at the onset of the covid-19 pandemic in 2020 with the express goal to revolutionise diagnosis of infectious diseases. Diagonal Bio’s team is led by experienced professionals in the biotechnology field, including COB Kerstin Jakobsson, interim CEO Karin Wehlin, CFO Per Heander, and a diverse board of directors. Diagonal's operations are based in Lund, Sweden and its scientific advisors include Prof. Vicent Pelechano (Karolinska Institute, Sweden), Prof. Christelle Prinz (Lund University, Sweden), Prof. Patrik Medstrand (Lund University), Prof. Tautgirdas Ruzgas (Malmö University, Sweden) and Kushagr Punyani (Spermosens AB).
1 to 10 staff
Epigenica
Epigenica is a life sciences technology company at the forefront of innovations in epigenetic research. The company’s EpiFinder platform enables researchers to perform comprehensive epigenetic studies at unprecedented speed, scalability, and affordability. Epigenica is building a portfolio of products based on the EpiFinder platform to offer comprehensive high-throughput profiling at different depths of detail with an array of possible starting materials. The platform is powered by the company’s patented and proprietary high-throughput, multiplex, quantitative ChIP-seq technology (hmqChIP), the first commercial kit of its kind. With the advantages of the EpiFinder platform, Epigenica is helping researchers advance biomedical research, drug discovery and development, precision medicine, diagnostics, and therapeutics for aging and longevity.
11 to 50 staff
Key2brain Ab
Key2Brain is a Swedish biotechnology company dedicated to developing next generation brain targeting therapies utilizing its proprietary blood-brain barrier-crossing technology. The technology enables efficient brain uptake and broad distribution into the brain and can be integrated into a wide range of therapeutic molecules. The pipeline is being developed internally and in partnerships where Key2Brain’s team leverages extensive industry experience in biologics and brain-targeting drugs, accelerating the translation from discovery to the clinic.
1 to 10 staff
Miris Holding Ab
Miris Holding AB is the parent company of the wholly-owned subsidiary Miris AB. All operating activities are conducted in the subsidiary Miris AB. For further information go to Miris is a global company developing, manufacturing, marketing and selling solutions for human milk analysis. The products are being used at neonatal intensive care units, milk banks and research centers worldwide. The purpose is to enable clinicians to individualize nutrition of breast milk through target fortification, giving preterm babies the best possible start in life. Our mission is to make individual nutrition, based on breast milk, available globally to improve neonatal health. Miris Holding AB is listed on Spotlight Stock Market, Sweden.
11 to 50 staff
Xbrane Biopharma Ab
Xbrane is a biopharmaceutical company specialized in high demand biosimilars and long acting injectables. We enable global health equality by bringing affordable drugs to treat underserved people suffering from critical diseases. Xbrane posses world leading expertise in developing true generics for injectable controlled release drugs and proprietary high-yield protein expression technology.
51 to 200 staff
Insingulo Ab
At InSingulo, we specialize in the characterization of drug interactions with complex targets down to the single molecule level. Our biosensing technology allows for drug profiling on membrane proteins embedded in their native environment. We enable drug screening programs against membrane proteins and other challenging therapeutic targets.
1 to 10 staff
Mycorena
At Mycorena, we are on a mission to significantly change how we produce and consume food. We believe in the power of fungi and want to pave the way for a sustainability revolution by offering the industry scalable, high-quality products. Through innovative technology, we develop sustainable mycelium-based solutions for the food industry. Our flagship product Promyc is a proprietary vegan mycoprotein with superior nutritional value in protein, fibre, vitamins, and minerals. With a neutral taste and a satisfying fibrous texture, Promyc offers the most demanded qualities in the alternative protein segment. What originated as a research project has grown into one of the fastest-growing companies in the industry. Since our founding in 2017, we have scaled from a small lab to Scandinavia’s largest demo production facility for mycoprotein. We are expanding further as we prepare to commence commercial production in our new Promyc Production Plant, the first of its kind in Scandinavia. Our vision is to be world-leading in fungi-based technology and drive the change in the food system for a sustainable tomorrow. The future of food is now.
51 to 200 staff
Zymiq Technology
ZymIQ is a Swedish life science company with the mission to bring highly innovative enzyme-based therapeutics and cosmetics to the global market. Science-based solutions, together with cutting-edge technology, are the foundation of our development of the next generation of antimicrobial solutions. All for the well-being of humans and animals.
11 to 50 staff
